PROK
PROK clinical trials: PROKIDNEY CORP.
Every trial on ClinicalTrials.gov where PROKIDNEY CORP. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 10
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PROK on the catalyst calendar · PROK registry changes
- Primary completion May 31, 2030Sponsor estimateNo phase registeredNCT06790498Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen ProductProkidney · Diabetic Kidney DiseaseEnrolling by invitationPROKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimateNo phase registeredNCT05918523A Long-Term Follow-Up Study of Participants Exposed to REACTProkidney · Diabetic Kidney DiseaseRecruitingPROKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2029Sponsor estimatePhase 3NCT05099770Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseaseProkidney · Type 2 Diabetes MellitusActive, not recruitingPROKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 20, 2025ActualPhase 2NCT05018416Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)Prokidney · Chronic Kidney DiseasesCompletedPROKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2023ActualPhase 2NCT02836574A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney DiseaseProkidney · Type 2 Diabetes MellitusCompletedPROKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 17, 2022ActualPhase 2NCT03270956A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney DiseaseProkidney · Type 2 Diabetes MellitusCompletedPROKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 19, 2024ActualPhase 1NCT05694169A Study of Participants With Chronic Kidney Disease Previously Treated With REACTProkidney · Diabetic Kidney DiseaseTerminatedPROKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 3, 2024ActualPhase 3NCT05286853A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney DiseaseProkidney · Type 2 Diabetes MellitusWithdrawnPROKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2023ActualPhase 1NCT04115345A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney...Prokidney · Chronic Kidney DiseaseCompletedPROKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2017ActualPhase 2NCT02525263Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)Prokidney · Chronic Kidney DiseaseTerminatedPROKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner